Arsenic Trioxide in Treating Patients With Urothelial Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have
recurrent cancer of the bladder or urinary tract. Arsenic trioxide may kill tumor cells that
have become resistant to standard chemotherapy regimens.